Drug Discovery & Development | Roche nabs European approval for time-saving formulation of Rituxan FiercePharma Swiss pharma giant Roche ($RHHBY) is pursuing that game plan for some of its hit biotech drugs--and today it scored a victory when European regulators approved a subcutaneous version of its cancer drug Rituxan (rituximab), known as MabThera overseas. Europe OKs New Formula of Roche Cancer Drug Halozyme Platform Wins EC Approval for Roche's MabThera SC EC approves Roche's SC formulation of MabThera for common forms of non ... |
